AcouSort AB Total Assets
AcouSort AB total assets. Based on the latest financial reports, AcouSort AB (ACOU) holds total assets worth Skr21.47 Million SEK (≈ $2.31 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see AcouSort AB market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of AcouSort AB (2013–2025)
Total assets of AcouSort AB from 2013 to 2025. This chart illustrates how AcouSort AB's total assets have evolved over time, based on quarterly financial data. See today's stock price for AcouSort AB for real-time trading data and today's change.
AcouSort AB - Asset Composition Analysis
AcouSort AB Total Assets Breakdown (December 2025)
AcouSort AB total assets breakdown as of December 2025. AcouSort AB's total assets of Skr21.47 Million consist of 72.9% current assets and 27.1% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 35.2% |
| Accounts Receivable | Skr434.00K | 2.4% |
| Inventory | Skr2.56 Million | 14.3% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr4.84 Million | 27.1% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how AcouSort AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of AcouSort AB to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AcouSort AB's current assets represent 72.9% of total assets in 2025, a decrease from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 35.2% of total assets in 2025, down from 87.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 27.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 27.1% of total assets.
AcouSort AB Competitors by Total Assets
Key competitors of AcouSort AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
AcouSort AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.41 | 4.27 | 0.58 |
| Quick Ratio | 1.20 | 3.77 | 0.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr4.81 Million | Skr16.52 Million | Skr-2.31 Million |
AcouSort AB - Advanced Valuation Insights
This section examines the relationship between AcouSort AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.00 |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | 45.2% |
| Total Assets | Skr17.89 Million |
| Market Capitalization | $7.49 Million USD |
Valuation Analysis
Below Book Valuation: The market values AcouSort AB's assets below their book value (0.42x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: AcouSort AB's assets grew by 45.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for AcouSort AB (2013–2025)
The table below shows the annual total assets of AcouSort AB from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr17.89 Million ≈ $1.93 Million |
+45.19% |
| 2024-12-31 | Skr12.32 Million ≈ $1.33 Million |
-64.29% |
| 2023-12-31 | Skr34.51 Million ≈ $3.71 Million |
-19.09% |
| 2022-12-31 | Skr42.66 Million ≈ $4.59 Million |
+16.67% |
| 2021-12-31 | Skr36.56 Million ≈ $3.93 Million |
+177.58% |
| 2020-12-31 | Skr13.17 Million ≈ $1.42 Million |
+63.92% |
| 2019-12-31 | Skr8.04 Million ≈ $864.69K |
-53.93% |
| 2018-12-31 | Skr17.44 Million ≈ $1.88 Million |
+252.52% |
| 2017-12-31 | Skr4.95 Million ≈ $532.38K |
-58.91% |
| 2016-12-31 | Skr12.04 Million ≈ $1.30 Million |
+4517.90% |
| 2015-12-31 | Skr260.70K ≈ $28.06K |
-71.67% |
| 2014-12-31 | Skr920.08K ≈ $99.02K |
-61.88% |
| 2013-12-31 | Skr2.41 Million ≈ $259.72K |
-- |
About AcouSort AB
AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, a module that enables in-line analysis of blood plasma from whole blood samples; Acous… Read more